Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

by Ysios Capital

Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer

Read more

Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea

by Ysios Capital

The MAF Test® is now available to oncologists and pathologists in South Korea and will benefit an estimated 34,000 new patients each year

Read more

CDTI invests in the InceptionBio fund, launched by Ysios to support the creation of biotech companies

by Ysios Capital

The SICC Innvierte fund of CDTI Innovación invests in InceptionBio, a fund aimed at promoting the creation of biotechnology companies and the development of early-stage technology transfer projects.

Read more

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

by Ysios Capital

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data

Read more

Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation

by Ysios Capital

InceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. The fund will primarily invest in technology transfer oppor...

Read more

Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical

by Ysios Capital

Joan Perelló and Arturo Urrios will lead a new vertical focused on company creation and early-stage biotech projects, with a strong focus on Spain.

Read more

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

by Ysios Capital

SparingVision, a clinical-stage genomic medicine company transforming the treatment of retinal diseases, today announced that it has successfully completed dosing in its Phase I/II PRODYGY clinical tr...

Read more

Telescope Biotech Fund Announces Annual Results: In Its First Year Since Launch in February 2025, It Achieves a Net Return of +52.5% in Its Gold Class

by Ysios Capital

La estrategia de inversión especializada ha permitido capitalizar el gran potencial de la innovación biomédica, impulsada además por una oleada de fusiones y adquisiciones.

Read more

Inbiomotion, a portfolio company of Ysios Capital, announces the inclusion of the MAF Test in the SEOM guidelines

by Ysios Capital

Inbiomotion has announced that its MAF Test® has been included in the 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, a key consensus document guiding clinical deci...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

A study led by IDIBELL and the Universit...

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

The research helps understand the biological basis of a rare neurodeve...

Photos Stream